CIRM Funded Clinical Trials

Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects


Donald Kohn
Investigator:
CIRM Grant:
Award Value:
$20,000,000
Trial Stage: 
Phase 2
Trial Status: 
Recruiting
Targeted Enrollment:
10
ClinicalTrials.gov ID:
Details: 

In ADA-SCID, allogeneic hematopoietic stem cell transplants (HSCTs) from non-matched sibling donors are a high risk procedure. Efficacy of chronic enzyme replacement therapy is uncertain in the long-term. Preliminary data indicates that OTL-101 -a stem cell gene therapy developed by UCLA and Orchard Therapeutics Limited - may significantly improve outcomes compared to available therapies.

Design: 

Comparability of cryopreserved product versus fresh product.

Goal: 

Primary: Safety. Secondary: Efficacy, gene marking, immune reconstitution. Registrational trial.

Status: 

Breakthrough Therapy Designation. Rare Pediatric Designation. Early evidence of safety and clinical efficacy in all treated patients.